Loading clinical trials...
Loading clinical trials...
Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)
Conditions
Interventions
Warfarin
Dabigatran Etexilate 150mg
Locations
87
United States
Arkansas Cardiology, PA
Little Rock, Arkansas, United States
Mission Cardiovascular Research Institute
Fremont, California, United States
University of California
Sacramento, California, United States
Mercy Medical Group, a service of Dignity Health Medical Foundation
Sacramento, California, United States
University of California
San Francisco, California, United States
Southwest Florida Research, LLC
Naples, Florida, United States
Start Date
April 28, 2015
Primary Completion Date
November 11, 2016
Completion Date
November 14, 2016
Last Updated
January 29, 2018
NCT05147792
NCT06935591
NCT05963698
NCT03546374
NCT04947657
NCT06686485
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions